Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

FDA approves drugs three to four months faster than the EMA

The United States medicines safety watchdog approves more new drugs and is faster than its peer agency in Europe, according to the results of a study published in the New England Journal of Medicine (online, 5 April 2017)[1].

Researchers found that the US Food and Drug Administration (FDA) gave the green light to 170 new drugs between 2011 and 2015, compared with 144 approved by the European Medicines Agency (EMA) in the same period. 

The median time it took for a drug to gain FDA approval during this time was 306 days, the researchers found, compared with 383 days for a drug to complete the EMA system.

New drugs for cancer and blood diseases were singled out by the authors as moving through the FDA system especially quickly, taking a median of 206 days compared to 379 days in Europe.

On the whole, the research shows that the FDA is working around three to four months faster than its European peer agency, confirming that the US agency has upped its pace in recent years.

A separate paper published in 2012 compared the time the FDA took to approve new drugs between 2001 and 2010 compared with the EMA as well as the Canadian drugs safety watchdog, Health Canada.

These results, also published in the New England Journal of Medicine (online, 14 June 2012)[2], revealed that the FDA was working around two to three months faster than the two other agencies.

The latest research comes at a time when the FDA’s drug approval system is being scrutinised as part of a government review of the US Prescription Drug User Fee Act — the law that determines the agency’s funding.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202570

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • FDA entrance

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.